- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
ESMO Open. 2019;4(4):e000532
Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
Cancer. 2019 Aug 07;:
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Mol Carcinog. 2019 Jul 29;:
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Lung Cancer. 2019 Aug;134:259-267
Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer.
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1228-1237
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group ...
Lung Cancer. 2019 Jul;133:48-55
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial.
BMC Cancer. 2019 Jun 07;19(1):552
Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario.
J Oncol Pharm Pract. 2019 Jun 02;:1078155219850299
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
J Clin Oncol. 2019 Jun 02;:JCO1900934
Oncologist. 2019 May 28;:
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group